Business Advisory Board

Scott Minick, PhD

ARCH Venture Partners; Former President and CEO of BIND Therapeutics, Inc.

Mr. Minick currently serves on the board of Chiasma, which has completed a phase 3 study of a novel oral therapeutic for acromegaly and did a successful IPO in July 2015 and Alzheon, which is developing a treatment for Alzheimer’s Disease.  He previously served as the President and CEO of BIND Therapeutics, Inc. from 2009 to 2015, where he built an broad cancer clinical pipeline and completed a successful IPO in 2013. He was a Managing Director of ARCH Venture Partners, a venture capital firm, and was instrumental in the startup, development and financing of numerous ARCH portfolio companies, including BIND Therapeutics. From 1995 to 1998, Mr. Minick was Director, President & Chief Operating Officer of SEQUUS Pharmaceuticals, Inc., a biopharmaceutical company developing the cancer therapeutic, Doxil®,  that was acquired by ALZA Corporation in 1999.

Mr. Minick received his postgraduate training in neurobiology at the Salk Institute, an MBA from Northwestern University and a BA from the University of California at San Diego.